文献速递自身炎症与 IgG4 相关病

VEXAS综合征临床表现与UBA1突变负荷的关联

Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden.
PubMed 文献 · Arthritis Rheumatol · 2025-09-21

基于Geisinger MyCode与Mount Sinai BioMe两个队列共192584名参与者的全外显子测序数据,鉴定出23例携带UBA1致病变异者(变异等位基因频率VAF范围2.9%-79%,69.6%为男性)。高VAF(>20%)组大细胞性贫血发生率高于低VAF(≤20%)组,VEXAS疾病严重程度与外显率随VAF升高而增加,低VAF者外显不全且症状较轻。

要点

  • 高VAF(>20%)组大细胞性贫血发生率为87.5%,高于低VAF(≤20%)组的27%(P=0.009)。
  • 遗传检测时高VAF组87.5%已出现大细胞性贫血,低VAF组为13.3%(P=0.001)。
  • 低VAF(尤其≤10%)者可最初无症状,之后才出现疾病表现。

核心结论

  • VEXAS综合征的疾病严重程度与外显率随UBA1变异等位基因频率(VAF)升高而增加。
  • 低VAF病例表现为外显不全,且疾病倾向于较轻。
  • 女性在低VAF中富集且症状较轻,提示对疾病严重程度具有保护作用。
  • 低VAF病例(尤其≤10%)可最初无症状,之后才发展出疾病。

研究设计与样本

  • 研究分析Geisinger MyCode社区健康倡议与Mount Sinai BioMe生物样本库共192584名参与者的全外显子测序数据,筛查UBA1致病性变异。
  • 在携带UBA1变异的个体中分析临床表现,共鉴定出23名参与者携带9种UBA1变异(VAF范围2.9%-79%,69.6%为男性)。

主要发现

  • 高VAF(>20%)病例较大细胞性贫血发生率高于低VAF(≤20%)病例(87.5% vs 27%,P=0.009)。
  • 遗传检测时高VAF病例中87.5%已出现大细胞性贫血,低VAF病例中为13.3%(P=0.001)。
  • 贫血或血小板减少的发生率在两组间无显著差异(P=0.53)。
  • 两例高VAF病例在大细胞增多出现后超过五年才于样本采集时出现贫血。
  • 一例伴有其他炎症症状的低VAF病例在样本采集五年后才出现大细胞性贫血。

关键数值与推荐

  • 高VAF定义为>20%,低VAF定义为≤20%。
  • 高VAF组大细胞性贫血发生率为87.5%,低VAF组为27%(P=0.009)。
  • 遗传检测时高VAF组大细胞性贫血比例为87.5%,低VAF组为13.3%(P=0.001)。
  • 贫血或血小板减少发生率的组间比较P=0.53。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a progressive systemic autoinflammatory disorder caused by somatic variants in UBA1 in blood. Previous analyses have shown discordant disease penetrance. In this study, we examine the associations between demographic features and UBA1 variant allele frequency (VAF) with disease manifestations. METHODS: Whole exome sequencing data from 192,584 participants from Geisinger MyCode Community Health Initiative and Mount Sinai BioMe Biobank were analyzed for disease-causing variants in UBA1. Clinical manifestations were analyzed across individuals with the UBA1 variant. RESULTS: Nine UBA1 variants (VAF range 2.9%-79%) in 23 participants (69.6% men) were identified. Cases with high VAF (>20%) developed macrocytic anemia more often (87.5%) than patients with low VAF (≤20%) variants (27%; P = 0.009). Specifically, at the time of genetic testing, 87.5% of high VAF cases had macrocytic anemia compared with 13.3% of low VAF cases (P = 0.001). However, there was no significant difference in the development of anemia or thrombocytopenia (P = 0.53). In two high VAF cases, macrocytosis developed more than five years before the time of sample collection, followed by anemia approximately at the time of sample collection. In one low VAF case with other inflammatory symptoms, macrocytic anemia did not develop until five years after sample collection. CONCLUSION: VEXAS syndrome disease severity and penetrance increase at higher VAFs. Low VAF cases demonstrate incomplete penetrance, and the disease tends to be milder in those with it. Female individuals are enriched in lower VAFs and have milder symptoms, suggesting a protective role against disease severity. Low VAF cases, especially ≤10%, can be initially asymptomatic and later develop disease.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Anderson M, Ercelen D, Richardson A, et al. Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden. Arthritis Rheumatol. 2025. PMID: 40976851. doi:10.1002/art.43327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。